- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Prasco begins distribution of doxercalciferol capsules
- Takeda starts phase-3 trials of vedolizumab
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
CAMBRIDGE, Mass. — An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.
Genzyme, owned by French drug maker Sanofi, compared the once-daily drug teriflunomide with Rebif (interferon beta-1a), made by Pfizer and Merck KGaA, in patients with relapsing MS in the 324-patient "TENERE" trial. Merck KGaA, based in Germany, operates under the name EMD Serono in the United States to avoid confusion with U.S.-based Merck & Co.
Teriflunomide in doses of 7 mg and 14 mg did not show superiority over Rebif on risk of treatment failure, defined as a disease relapse or permanent discontinuation of treatment for any reason. Among patients receiving the 7-mg dose, 48.6% did not show risk of treatment failure, compared with 37.8% of those taking the 14-mg dose, and 42.3% of those taking Rebif.
Estimated annual relapse rates were higher among patients taking teriflunomide in the 7-mg dose than among those taking the 14-mg dose or Rebif, while patients taking Rebif showed higher rates of permanent treatment discontinuation than those taking teriflunomide.